IFITM3

Across TCGA pan-cancer cohorts, IFITM3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IFITM3 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IFITM3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IFITM3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, PDAC, and UCEC are the cancer types where IFITM3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.913	0.645	.010	30	view →
PDAC	DFS	Median	III,IV	0.365	0.888	.002	23	view →
UCEC	DFS	Quartile	II,III,IV	0.221	0.889	.003	14	view →
LUAD	OS	Median	All	0.565	0.858	.029	8	view →
LSCC	DFS	Quartile	All	1.000	0.453	.026	2	view →
CCRCC	OS	Tertile	All	0.802	0.932	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IFITM3–HNSC (DFS)

Open the HNSC breakdown →